BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Core Insights - Bezisterim demonstrates significant potential in modulating biological aging and inflammation, showing a 2 to 4 years age deceleration advantage in patients compared to placebo [1][3][11] Group 1: Clinical Data and Findings - Clinical data presented at the 11th Aging Research and Drug Discovery Meeting indicates that bezisterim affects biological aging and chronic low-grade inflammation [2][3] - Patients treated with bezisterim exhibited age deceleration advantages across various biological clocks: 3.68 years on SkinBlood Clock, 4.77 years on Inflammation Age Clock, 5.0 years on Hannum Age Clock, 1.92 years on GrimAge Clock, and 3.71 years on PhenoAge Clock [3][11] - Bezisterim is associated with 1.5 to 2.3 "fold enrichment" in gene pathways related to neurodegenerative disorders, indicating its potential to influence gene expression significantly [4][9] Group 2: Mechanism of Action - Bezisterim modulates DNA methylation of proinflammatory genes, promoting the transition from M1 proinflammatory macrophages to M2 anti-inflammatory macrophages [1][3][9] - The drug has shown the ability to significantly modulate the methylation levels of genes involved in inflammatory pathways, potentially reducing the production of inflammatory factors such as TNFα and IL6 [4][9][10] - Bezisterim is believed to be the first drug candidate to demonstrate an impact on DNA methylation and age deceleration in a clinical trial context [3][5] Group 3: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease [12] - The company is investigating bezisterim for conditions such as Alzheimer's disease and Parkinson's disease, with promising results from Phase 2 and Phase 3 clinical trials [11][12] - BioVie is also developing BIV201, an orphan drug candidate for treating ascites due to chronic liver cirrhosis, which has received FDA Fast Track status [12]